Zymeworks Inc. (ZYME) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $23.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Zymeworks is a clinical-stage biopharma pursuing a royalty aggregation strategy with zanidatamab (Ziihera) as its lead asset, approved for HER2+ biliary tract cancer and licensed to Jazz (global ex-Asia) and BeOne (Asia). Revenue consists of milestones ($69.9M in 2025) and... Read more
Sell if holding. Engine safety override at $23.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Zymeworks Inc.
Latest news
- NEWS Reported Sunday, Zymeworks Presents Phase 1 Data For ZW191 ADC Showing 78.6% cORR In FRα-Positive And 47.4% In FRα-Negat — benzinga Jun 15, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Zymeworks, Maintains $46 Price Target — benzinga Jun 3, 2026 positive
- NEWS Zymeworks Announces $125M Buyback Plan — benzinga May 14, 2026 positive
- NEWS Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $34 — benzinga May 8, 2026 positive
- NEWS Zymeworks Q1 EPS $(0.59) Down From $(0.30) YoY, Sales $2.408M Down From $27.110M YoY — benzinga May 7, 2026 negative
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyJazz and BeOne (zanidatamab partners)10-K Item 1A: 'We depend on our collaborative relationships with Jazz, BeOne and J&J to further develop and commercialize zanidatamab'
- HIGHpipelinezanidatamab (Ziihera)10-K Item 1A: 'We have only one product approved for commercial sale ... other than the receipt of royalties relating to sales of zanidatamab'
Material Events(8-K, last 90d)
- 2026-04-01Item 5.02LOWKristin Stafford appointed as EVP, CFO of Zymeworks effective April 1, 2026. Prior role: SVP, Chief Accounting Officer at Royalty Pharma plc since December 2018. No family relationships or conflicts cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -126.3%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $23.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $21.63. Score 5.3/10, moderate confidence.
Take-profit target: $34.13 (+48.3% upside). Prior stop was $21.63. Stop-loss: $21.63.
Concentration risk — Counterparty: Jazz and BeOne (zanidatamab partners); Concentration risk — Pipeline: zanidatamab (Ziihera); Quality below floor (2.2 < 4.0).
Zymeworks Inc. trades at a P/E of N/A (forward 33.5). TrendMatrix value score: 4.5/10. Verdict: Sell.
20 analysts cover ZYME with a consensus score of 4.3/5. Average price target: $39.
What does Zymeworks Inc. do?Zymeworks is a clinical-stage biopharma pursuing a royalty aggregation strategy with zanidatamab (Ziihera) as its lead...
Zymeworks is a clinical-stage biopharma pursuing a royalty aggregation strategy with zanidatamab (Ziihera) as its lead asset, approved for HER2+ biliary tract cancer and licensed to Jazz (global ex-Asia) and BeOne (Asia). Revenue consists of milestones ($69.9M in 2025) and royalties on Ziihera sales; wholly-owned pipeline includes ADCs (ZW191, ZW251) and bispecifics in Phase 1.